Pharvaris (NASDAQ:PHVS - Free Report) - Investment analysts at Wedbush issued their FY2029 earnings per share (EPS) estimates for shares of Pharvaris in a note issued to investors on Monday, April 7th. Wedbush analyst L. Chico expects that the company will earn $5.99 per share for the year. The consensus estimate for Pharvaris' current full-year earnings is ($2.71) per share.
Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings data on Monday, April 7th. The company reported ($0.68) earnings per share for the quarter, beating analysts' consensus estimates of ($0.74) by $0.06.
Separately, JMP Securities raised their price objective on shares of Pharvaris from $46.00 to $55.00 and gave the company a "market outperform" rating in a research report on Friday, January 31st.
Check Out Our Latest Stock Analysis on Pharvaris
Pharvaris Stock Up 0.6 %
PHVS traded up $0.07 during trading on Wednesday, reaching $12.07. The stock had a trading volume of 3,950 shares, compared to its average volume of 71,398. The firm has a market capitalization of $631.14 million, a price-to-earnings ratio of -4.31 and a beta of -2.84. The stock has a 50 day moving average of $15.55 and a two-hundred day moving average of $18.36. Pharvaris has a 1-year low of $11.51 and a 1-year high of $25.50.
Hedge Funds Weigh In On Pharvaris
A number of institutional investors have recently modified their holdings of PHVS. Soleus Capital Management L.P. boosted its position in shares of Pharvaris by 36.2% in the fourth quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company's stock valued at $15,617,000 after acquiring an additional 216,483 shares during the period. FMR LLC raised its stake in Pharvaris by 3.6% during the 4th quarter. FMR LLC now owns 5,395,370 shares of the company's stock valued at $103,429,000 after purchasing an additional 189,714 shares during the last quarter. Octagon Capital Advisors LP boosted its holdings in Pharvaris by 25.4% in the 4th quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company's stock valued at $14,914,000 after purchasing an additional 157,530 shares during the period. Price T Rowe Associates Inc. MD grew its position in Pharvaris by 36.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company's stock worth $8,510,000 after purchasing an additional 118,408 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in shares of Pharvaris by 483.9% during the 4th quarter. Northern Trust Corp now owns 91,932 shares of the company's stock worth $1,762,000 after purchasing an additional 76,188 shares during the period.
About Pharvaris
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Featured Stories
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
